Animal models of Alzheimer's disease: A road full of pitfalls;Modélisation de la maladie d'Alzheimer: Un parcours semé d'embûches

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 3, Issue 4, 2005, Pages 261-270

  Delacourte, André ^a   Buée, Luc ^a  

^a INSERM   (France)

Author keywords

Alzheimer's disease; APP; Models; Physiopathology; Tau

Indexed keywords

AMYLOID PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN INJURY; DEGENERATIVE DISEASE; HUMAN; MEMORY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; HISTORY, 20TH CENTURY; HUMANS; TAU PROTEINS;

EID: 28944431913     PISSN: 17601703     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 1995; 8: 429-31.
2. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-6.
3. Brion JP, Flament-Durand J, Dustin P. Alzheimer's disease and tau proteins. Lancet 1986; 2: 1098.
4. Flament S, Delacourte A. Abnormal tau species are produced during Alzheimer's disease neurodegenerating process. FEBS Lett 1989; 247: 213-6.
5. Goedert M, Klug A. Tau protein and the paired helical filament of Alzheimer's disease. Brain Res Bull 1999; 50: 469-70.
6. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
7. St George-Hyslop PH. Role of genetics in tests of genotype, status, and disease progression in early-onset Alzheimer's disease. Neurobiol Aging 1998; 19: 133-7.
8. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996; 19: 53-77.
9. Perry G, Smith MA. Is oxidative damage central to the pathogenesis of Alzheimer disease? Acta Neurol Belg 1998; 98: 175-9.
10. Kalaria RN. Microglia and Alzheimer's disease. Curr Opin Hematol 1999; 6:15-24.
11. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 2002; 59: 59-66.
12. Grant WB, Campbell A, Itzhaki RF, Savory J. The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimers Dis 2002; 4: 179-89.
13. Goate AM. Monogenetic determinants of Alzheimer's disease: APP mutations. Cell Mol Life Sci 1998; 54: 897-901.
14. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
15. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
16. Buée L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999; 9: 681-93.
17. Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65.
18. Buée L, Bussiere T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
19. Spillantini MG, Van Swieten JC, Goedert M. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics 2000; 2: 193-205.
20. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002; 59: 398-407.
21. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995; 45: 461-6; [see comments].
22. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8; (discussion 278-84).
23. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APR Science 2001; 293: 1487-91.
24. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301I tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-5.
25. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-21.
26. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 2005; aug 23.
27. Turner PR, O'Connor K, Täte WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003; 70: 1-32.
28. Cao X, Sudhof TC. A transcriptively active complex of APP with Fe65 and histone acetyltransferase tip60. Science 2001; 293: 115-20.
29. Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 2004; 279: 24601-11.
30. Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 2005; 46: 541-54.
31. Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages in Alzheimer's disease. J Neurochem 2002; 81: 663-72.
32. Vingtdeux V, Hamdane M, Compel M, Begard S, Drobecq H, Ghestem A, et al. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis 2005; jun 2.
33. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 2003; 85: 1581-91.
34. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100: 10417-22.
35. Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 2004; 165: 1289-300.
36. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
37. Schenk D. Hopes remain for an Alzheimer's vaccine. Nature 2004; 431: 398.
38. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. A beta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-32.
39. Bieler S, Soto C. Beta-sheet breakers for Alzheimer's disease therapy. Curr Drug Targets 2004; 5: 553-8.
40. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-38.
41. Petit A, Pasini A, Alves Da Costa C, Ayral E, Hernandez JF, Dumanchin-Njock C, et al. JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo. J Neurosci Res 2003; 74: 370-7.
42. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 2004; 26: 365-75.
43. Gutierrez-Zepeda A, Luo Y. Testing the amyloid toxicity hypothesis of Alzheimer's disease in transgenic Caenorhabditis elegans model. Front Biosci 2004; 9: 3333-8.
44. Neve RL. A beta may be a planet, but APP is central. Neurobiol Aging 2001; 22: 151-4.
45. Lee HG, Casadesus G, Zhu X, Joseph JA, Perry G, Smith MA. Perspectives on the amyloid-beta cascade hypothesis. J Alzheimers Dis 2004; 6: 137-45.
46. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476-81.
47. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293: 711-4.
48. Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics 2003; 165: 1233-42.
49. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 2003; 100: 9980-5.
50. Delobel P, Flament S, Hamdane M, Delacourte A, Vilain JP, Buée L. Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3beta and PKA kinase activities. FEBS Lett 2002; 516: 151-5.
51. Delobel P, Flament S, Hamdane M, Jakes R, Rousseau A, Delacourte A, et al. Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation. J Biol Chem 2002; 277: 9199-205.
52. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990-5.
53. Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem 2003; 278: 34026-34.
54. Hamdane M, Smet C, Sambo AV, Leroy A, Wieruszeski JM, Delobel P, et al. Pin1: a therapeutic target in Alzheimer neurodegeneration. J Mol Neurosci 2002; 19: 275-87.
55. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2005; jul 26.